Filtered By:
Source: American Heart Journal
Condition: Bleeding
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 167 results found since Jan 2013.
Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ConclusionsMorbidly obese AF patients treated with rivaroxaban had comparable risk of ischemic stroke/systemic embolism and major bleeding as those treated with warfarin, but lower healthcare resource utilization and costs.
Source: American Heart Journal - February 21, 2019 Category: Cardiology Source Type: research
Association of Frailty and Cognitive Impairment with benefits of Oral anticoagulation in patients with atrial fibrillation
ConclusionThose with cognitive impairment or frailty in AF had higher predicted risk for stroke and higher observed mortality, yet were less likely to be treated with OAC. Despite this, the benefits of OAC were similar in patients with and without cognitive impairment or frailty.
Source: American Heart Journal - January 30, 2019 Category: Cardiology Source Type: research
Radial versus femoral vascular access in ST-elevation myocardial infarction: Are the results of femoral operators unfairly represented in observational research?
ConclusionDefault femoral operators achieved comparable outcomes when compared to default radial operators. The less favorable outcomes observed in FA cases may result from its selective use by radial operators in high risk cases.
Source: American Heart Journal - January 16, 2019 Category: Cardiology Source Type: research
Rationale and design for AMPLATZER™ amulet™ left atrial appendage Occluder IDE randomized controlled trial (amulet IDE trial)
Publication date: Available online 21 December 2018Source: American Heart JournalAuthor(s): Dhanunjaya Lakkireddy, Stephan Windecker, David Thaler, Lars Sondergaard, John Carroll, Michael R Gold, Hongfei Guo, Kyle J Brunner, James B Hermiller, Hans-Christoph Diener, Boris Schmidt, Lee MacDonald, Moussa Mansour, Brijeshwar Maini, Joseph LevineAbstractAimsThe Amulet IDE Trial is an ongoing, prospective, randomized, multi-national trial, designed to evaluate the safety and effectiveness of the AMPLATZER™ Amulet™ Left Atrial Appendage Occluder for stroke prevention in comparison to the WATCHMAN Left Atrial Appendage Closur...
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research
Immediate unselected coronary angiography versus delayed triage in survivors of out-of-hospital cardiac arrest without ST-segment elevation: Design and rationale of the TOMAHAWK trial
ConclusionThe TOMAHAWK trial will address the unresolved issue of timing and general indication of angiography after OHCA without ST-segment elevation.
Source: American Heart Journal - December 12, 2018 Category: Cardiology Source Type: research
Outcomes of Apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial
ConclusionsMulti-morbidity is prevalent among the population with AF; efficacy and safety of apixaban is preserved in this subgroup supporting extension of trial results to the most complex AF patients.Clinical trial registrationClinicalTrials.gov (NCT00412984).
Source: American Heart Journal - November 23, 2018 Category: Cardiology Source Type: research
EdoxabaN Versus standard of care and theIr effectS on clinical outcomes in pAtients havinG undergonE Transcatheter Aortic Valve Implantation in Atrial Fibrillation—Rationale and design of the ENVISAGE-TAVI AF trial
Publication date: November 2018Source: American Heart Journal, Volume 205Author(s): Nicolas M. Van Mieghem, Martin Unverdorben, Marco Valgimigli, Roxana Mehran, Eric Boersma, Usman Baber, Christian Hengstenberg, Minggao Shi, Cathy Chen, Shigeru Saito, Roland Veltkamp, Pascal Vranckx, George D. DangasTranscatheter aortic valve implantation, also called transcatheter aortic valve replacement (TAVR), is the treatment of choice for patients with severe aortic stenosis and intermediate to high operative risk. A significant portion of TAVR patients have atrial fibrillation (AF) requiring chronic oral anticoagulation. In moderate...
Source: American Heart Journal - August 30, 2018 Category: Cardiology Source Type: research
Rationale and design of the EVOLVE short DAPT study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention
ConclusionThe EVOLVE Short DAPT study will prospectively define the safety of DAPT discontinuation at 3 months in high bleeding risk patients treated with the SYNERGY stent.
Source: American Heart Journal - August 17, 2018 Category: Cardiology Source Type: research
Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Otavio Berwanger, Jose C. Nicolau, Antonio C. Carvalho, Lixin Jiang, Shaun Goodman, Stephen J. Nicholls, Alexander Parkhomenko, Oleg Averkov, Carlos Tajer, Germán Malaga, Jose F. Kerr Saraiva, Francisco Fonseca, Helio P. Guimaraes, Pedro G.M. de Barros e Silva, Lucas P. Damiani, Denise M. Paisani, Camila M.R. Lasagno, Carolina T. Candido, Nanci Valeis, Diogo D.F. MoiaAbstractBackgroundThe safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain.Objectives...
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
Variation in post-TAVR antiplatelet therapy utilization and associated outcomes: Insights from the STS/ACC TVT registry®
ConclusionsIn the U.S. the majority of patients were discharged on DAPT following TAVR. Practice patterns varied significantly among hospitals. Patients discharged with DAPT had a similar adjusted risk of mortality, stroke and MI compared to antiplatelet monotherapy, though risk for bleeding was significantly higher. Future investigation is needed to define the optimal antiplatelet therapy for patients undergoing TAVR.
Source: American Heart Journal - July 10, 2018 Category: Cardiology Source Type: research
Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
ConclusionsA bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial
Publication date: August 2018Source: American Heart Journal, Volume 202Author(s): Otavio Berwanger, Jose C. Nicolau, Antonio C. Carvalho, Lixin Jiang, Shaun Goodman, Stephen J. Nicholls, Alexander Parkhomenko, Oleg Averkov, Carlos Tajer, Germán Malaga, Jose F. Kerr Saraiva, Francisco Fonseca, Helio P. Guimaraes, Pedro G.M. de Barros e Silva, Lucas P. Damiani, Denise M. Paisani, Camila M.R. Lasagno, Carolina T. Candido, Nanci Valeis, Diogo D.F. MoiaAbstractBackgroundThe safety and efficacy of ticagrelor in patients with ST-elevation myocardial infarction (STEMI) treated with fibrinolytic therapy remain uncertain.Objectives...
Source: American Heart Journal - July 5, 2018 Category: Cardiology Source Type: research
Safety and efficacy of non –vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial
Conclusions A bivariate analysis that simultaneously characterizes both risk and benefit demonstrates that riva- and dabi-based regimens were both favorable over VKA plus dual antiplatelet therapy among patients with atrial fibrillation undergoing PCI.
Source: American Heart Journal - July 4, 2018 Category: Cardiology Source Type: research
